Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefin...
Source: Johnson and Johnson - June 12, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 news from Annals of Internal Medicine
(American College of Physicians) Experts suggest limited and careful use of corticosteroids as one of several strategies to curtail the syndemic of mucormycosis, or 'black fungus,' a fungal infection characterized by blackening or discoloration over the face, breathing difficulties, and other serious symptoms, that has recently emerged in India. A commentary from Washington University School of Medicine and the University of Massachusetts Medical School is published in Annals of Internal Medicine. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 7, 2021 Category: Infectious Diseases Source Type: news

What Are Some Indications for Using Dexamethasone?
Discussion Corticosteroids are a group of drugs which can be naturally or synthetically produced. Naturally occurring substances are produced in the adrenal gland, and are protein-bound (primarily corticosteroid-binding globulin and albumin). In the target tissues, they may need to be converted to an active substance. They are then reduced, oxidized, hydroxylated or conjugated as measures to inactivate them. Synthetic steroids have less protein binding and depending on their structure are more or less resistant to inactivation. Prednisone is the glucocorticoid most often used for treatment, especially as it has a short hal...
Source: PediatricEducation.org - June 7, 2021 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Mitigating the impacts of COVID-19: where are the mental health trials?, Lancet Psychiatry
COVID-19 prompted rapid mobilisation of health services and medical science in the face of unprecedented challenges. When COVID-19 emerged in 2020, medical science delivered, and delivered quickly. Using large-scale multicentre trials, researchers in partnership with health services established the ability of cheap and scalable interventions (such as corticosteroids) to save lives, and rapidly showed the futility of anecdotally endorsed repurposed drugs (such as hydroxychloroquine). The effectiveness of vaccinations was quickly established in phase 2 and 3 trials, providing the confidence to roll out successful vaccine pro...
Source: Current Awareness Service for Health (CASH) - June 4, 2021 Category: Consumer Health News Source Type: news

Drug-Induced Immunosuppression Examined in U.S. Adults
WEDNESDAY, June 2, 2021 -- Overall, 2.8 percent of a national cohort of commercially insured U.S. adults meet criteria for drug-induced immunosuppression, of whom 67.7 percent receive oral corticosteroids, according to a research letter published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 2, 2021 Category: Pharmaceuticals Source Type: news

Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A ...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Add-On Voclosporin Improves Outcome in Lupus Nephritis Add-On Voclosporin Improves Outcome in Lupus Nephritis
Voclosporin plus MMF and low-dose corticosteroids improves renal response rates compared with use of these agents alone in patients with in lupus nephritis, according to a company-funded study.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 1, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news

Insufficient data on use of inhaled corticosteroids to treat COVID-19, EMA
EMA's COVID-19 taskforce (COVID-ETF) is advising healthcare professionals that there is currently insufficient evidence that inhaled corticosteroids are beneficial for people with COVID-19. Although the taskforce found no safety risks from studies so far, it could not exclude the possibility of harm from the use of inhaled corticosteroids in patients with COVID-19 who have normal levels of oxygen. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 28, 2021 Category: Consumer Health News Source Type: news

Corticosteroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials, Medicine
Review of 8 RCTs (n=7,737) found the odds of mortality and need of mechanical ventilation were significantly lower in patients who received corticosteroids vs standard of care (OR 0.85 [95% CI: 0.76; 0.95] P=0.003) and (OR = 0.76 [95% CI: 0.59; 0.97] P=0.030), respectively. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 26, 2021 Category: Consumer Health News Source Type: news

Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Long-Term ERLEADA ® (apalutamide) Patient-Reported Outcomes Data in Metastatic Castration-Sensitive Prostate Cancer Demonstrate Maintenance of Health-Related Quality of Life for Patients
May 26, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced patient-reported outcomes (PRO) data from the pre-specified final analysis of the Phase 3 TITAN study in patients with metastatic castration-sensitive prostate cancer (mCSPC). The TITAN study previously demonstrated statistically significant improvement in overall survival (OS) after a median follow-up of 44 months in patients receiving ERLEADA® plus androgen deprivation therapy (ADT).1 The new PRO data showed that the addition of ERLEADA® to ADT maintained patients’ health-related quality of lif...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of RYBREVANTTM (amivantamab-vmjw) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.[1] RYBREVANTTM is the first fully-human, bispecific antibody approved for the treatment of patients with NSCLC t...
Source: Johnson and Johnson - May 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Corticosteroid Bursts May Increase GI Bleeding Risk in Children Corticosteroid Bursts May Increase GI Bleeding Risk in Children
Oral corticosteroid bursts are associated with an increased risk of gastrointestinal bleeding, sepsis, and pneumonia during the month after treatment initiation, according to a cohort study in Taiwan.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - May 5, 2021 Category: Emergency Medicine Tags: Pediatrics News Source Type: news

Topical Corticosteroid Use in Pregnancy Not Tied to SGA, LBW
WEDNESDAY, May 5, 2021 -- Topical corticosteroid use in pregnancy is not associated with increased risks for small for gestational age (SGA) or low birth weight, according to a study published online May 5 in JAMA Dermatology. Niklas Worm... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 5, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, The Lancet
In patients with hypoxia and evidence of systemic inflammation (C-reactive protein ≥75 mg/L), the addition of tocilizumab to usual standard of care (82% receiving systemic corticosteroids) reduced 28-day mortality (31% v 35%; rate ratio 0.85; 95% CI 0.76–0.94; p=0.0028). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 4, 2021 Category: Consumer Health News Source Type: news

Featured Review: Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma
New Cochrane Review on the efficacy and safety of inhalers for those with mild asthma published on World Asthma Day.World Asthma Day on 5 May is an annual event on organized by the  Global Initiative for Asthma (GINA) to improve asthma awareness and care around the world.Cochrane Airways works with authors (typically clinicians and researchers) to produce systematic reviews on chronic obstructive pulmonary disease (COPD), bronchiectasis and other lung diseases, and asthma. We asked Dr Timothy Hinks, one of the Cochrane Review authors, about the findings of this recent review.For those with mild asthma, ...
Source: Cochrane News and Events - April 29, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context, The Lancet Respiratory Medicine
Article reviews clinical& methodological heterogeneity of studies of IL-6 antagonists,& considers how this might have influenced reported treatment effects. Severity of illness and concomitant corticosteroids are among factors that might have contributed to inconsistent results (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 29, 2021 Category: Consumer Health News Source Type: news

Horizontal transmission can cause severe and persistent eye inflammation
This study highlights a novel mode of transmission for HTLV-1 uveitis. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 27, 2021 Category: Infectious Diseases Source Type: news

Separate Corticosteroid Injections From COVID Vaccine by 2 Weeks Separate Corticosteroid Injections From COVID Vaccine by 2 Weeks
Clinicians may still want to time elective corticosteroid injections at least two weeks before or after receipt of this vaccine, according to a group of doctors writing on behalf of the Spine Intervention Society.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - April 26, 2021 Category: Orthopaedics Tags: Infectious Diseases News Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); ho...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 8th April 2021)
This guideline covers the management of COVID-19 for children, young people and adults in all care settings. It brings together existing recommendations on managing COVID-19 so that healthcare staff and those planning and delivering services can find and use them more easily. The guideline includes new recommendations on therapeutics, and we will update the guideline further as new evidence emerges. 8 April 2021, Recommendations for using corticosteroids, tocilizumab and sarilumab to treat COVID-19 were added (including the evidence and rationale for making the recommendations). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 15, 2021 Category: Consumer Health News Source Type: news

Topical Dermatologic Corticosteroids: in Vivo Bioequivalence
Biopharmaceutics (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 13, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Common asthma drug speeds up COVID-19 recovery in high-risk patients
A common corticosteroid shortens COVID-19 recovery times for patients aged over 50 who are at high risk of developing severe illness, a groundbreaking GP-led trial has found. (Source: GP Online News)
Source: GP Online News - April 12, 2021 Category: Primary Care Tags: Coronavirus Source Type: news

Common asthma drug speeds up COVID-19 recovery in community for high-risk patients
A common corticosteroid shortens COVID-19 recovery times for patients aged over 50 who are at high risk of developing severe illness, a groundbreaking GP-led trial has found. (Source: GP Online News)
Source: GP Online News - April 12, 2021 Category: Primary Care Tags: Coronavirus Source Type: news

Sobrin Receives Research to Prevent Blindness Physician-Scientist Award
Lucia Sobrin, MD, MPH, of the Division of Ophthalmology, won the Physician-Scientist Award from Research to Prevent Blindness (RPB) for her work in identifying genes that influence the risk of developing ocular hypertension after corticosteroid use. (Source: BWH News)
Source: BWH News - March 29, 2021 Category: Hospital Management Source Type: news

Remdesivir and clinical improvement in hospitalized patients with COVID-19
(JAMA Network) This comparative effectiveness research study that included a high proportion of non-White individuals assesses whether remdesivir administered alone or with corticosteroids is associated with time to clinical improvement or time to death in patients hospitalized with confirmed COVID-19. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - March 24, 2021 Category: International Medicine & Public Health Source Type: news

Corticosteroids in COVID-19: Should It Be Standard-of-Care? Corticosteroids in COVID-19: Should It Be Standard-of-Care?
Corticosteroids have provided a useful treatment option for COVID-19, but the benefits and drawbacks of this therapy should be considered.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 17, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Checkpoint Inhibitor Rheumatic Complications Often Arise Late Checkpoint Inhibitor Rheumatic Complications Often Arise Late
Most checkpoint inhibitor-induced rheumatic complications in patients with cancer can be treated successfully with corticosteroids, albeit often at considerably higher doses than rheumatologists typically use in managing rheumatoid arthritis, says an expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 16, 2021 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Disentangling the complex bidirectional associations between COVID-19 and psychiatric disorder, Lancet Psychiatry
In The Lancet Psychiatry, Maxime Taquet and colleagues reported that survivors of COVID-19 appear to be at increased risk of psychiatric sequelae, and that a psychiatric diagnosis might be an independent risk factor for COVID-19. We are concerned that several limitations might weaken the bidirectional associations between COVID-19 and psychiatric disorder. First, evidence suggests that the medical isolation of hospitalised patients might have a negative effect on their mental wellbeing and behaviour, with higher levels of depression and anxiety among isolated patients.Therefore, the psychiatric sequelae of COVID-19 might r...
Source: Current Awareness Service for Health (CASH) - March 3, 2021 Category: Consumer Health News Source Type: news

Transplant patients may not need steroid treatment in the long run
(University of Cincinnati) Corticosteroids in kidney transplant patients may not be needed past a seven-day post surgery period, according to a University of Cincinnati College of Medicine study. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 24, 2021 Category: International Medicine & Public Health Source Type: news

Epidural Steroids and Infection Risk After Spine Surgery Epidural Steroids and Infection Risk After Spine Surgery
A new study examines the question of whether preoperative lumbar epidural corticosteroid injections are associated with an increased risk for infection after spinal surgery. Is there a link?Spine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 18, 2021 Category: Consumer Health News Tags: Orthopaedics Journal Article Source Type: news

Effectiveness of corticosteroids in patients with sepsis or septic shock using the new third international consensus definitions (Sepsis-3): A retrospective observational study, PLoS One 15(12): e0243149
Conclusions: In patients with sepsis or septic shock, intravenous corticosteroids were not associated with a higher in-hospital survival up to 50 days regardless of the sepsis definitions. Further research may be necessary to definitively confirm effectiveness in real-world practice. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 11, 2021 Category: Consumer Health News Source Type: news

Janssen Announces Treatment with ERLEADA ® (apalutamide) Significantly Improved Overall Survival in Patients with Metastatic Castration-Sensitive Prostate Cancer
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the final analysis of the Phase 3 TITAN study, which demonstrated the continued statistically significant benefit of the addition of ERLEADA® (apalutamide) to androgen deprivation therapy (ADT) in overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC), regardless of extent of disease, when compared to placebo plus ADT.[1] Results will be featured in an oral presentation at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cance...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo a...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Podcast: What are the benefits and risks of giving corticosteroids to pregnant women at risk of premature birth?
Monday, February 1, 2021 (Source: Cochrane News and Events)
Source: Cochrane News and Events - February 1, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Corticosteroid Therapy for COVID-19-Related ARDS Corticosteroid Therapy for COVID-19-Related ARDS
What role do corticosteroids have in the treatment of ARDS caused by COVID-19? How might this therapy impact the risk of in-hospital mortality in these patients?Critical Care (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - January 19, 2021 Category: Intensive Care Tags: Critical Care Journal Article Source Type: news

Corticosteroid Therapy for COVID-19-Related ARDS Corticosteroid Therapy for COVID-19-Related ARDS
What role do corticosteroids have in the treatment of ARDS caused by COVID-19? How might this therapy impact the risk of in-hospital mortality in these patients?Critical Care (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 19, 2021 Category: Consumer Health News Tags: Critical Care Journal Article Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
THOUSAND OAKS, Calif., Dec. 21, 2020 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced the SOURCE trial did not meet the primary endpoint of a statistically significant reduction in the daily oral corticoster... Biopharmaceuticals Amgen, AstraZeneca, tezepelumab, asthma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 22, 2020 Category: Pharmaceuticals Source Type: news

Position statement: Use of investigational immunomodulatory medicines for COVID-19 Interim support for UK hospital clinicians, RCP
Key messages • A subset of patients with COVID-19 may experience an exaggerated hyperinflammatory response • COVID-19 associated hyperinflammation predominantly involves the lung however may progress to secondary haemophagocytic lymphohistocytosis (sHLH) which is a systemic and multi-organ condition with significant morbidity and mortality • CTAG strongly recommends systemic corticosteroids for patients who fit definitions of WHOdefined severe or critical COVID-19, or in patients who otherwise have a new oxygen requirement • CTAG also recommends not to use corticosteroid therapy in patients with...
Source: Current Awareness Service for Health (CASH) - December 21, 2020 Category: Consumer Health News Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Patient Care - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Administration and Leadership - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Latest News - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS: Journal of Emergency Medical Services News - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Operations - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Emergency Considerations in COVID-19 Vaccine Administration
Conclusion The joint response of science and medicine to develop safe and effective COVID-19 vaccines has been brisk and productive. Distribution efforts will now be the next step in limiting the breadth of this pandemic. EMS agencies will play a key role in some areas in the administration of vaccinations for their communities. The authors suggest that to better clarify the side effects of the COVID-19 vaccines, EMS systems must maintain a log of the type and incidence of adverse events following vaccine administration, EMS responses to the adverse events, as well as those patients’ outcomes from this manageme...
Source: JEMS Special Topics - December 16, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Coronavirus Exclusives EMS EMT Paramedic Source Type: news

Extraction with an electric motor-driven handpiece may still cause subcutaneous emphysema - A case report
This article reported a case of SE around the paraorbital and submandibular regions through extractions of teeth 28 and 38. This 20-year-old man came to the emergency room at night with the major complaint of pain and discomfort during swallowing. Sudden swelling at his left face during extractions of teeth 28 and 38 three hours ago was mentioned. The original surgeon who performed the odontectomy was aware of the SE after removing the surgical drape and specific post-operation instructions were given as follows: immediate hospital care may be needed if the patient encountered difficulties in swallowing or any worsen compl...
Source: Dental Technology Blog - December 14, 2020 Category: Dentistry Source Type: news

Featured Review: Antenatal corticosteroids for accelerating fetal lung maturation in women at risk of preterm birth
The Cochrane review aboutantenatal steroids in reducing risk of infant mortality and morbidity is animportant one inCochrane's history. Cochrane's logo is based on the forest plot from the original  publication in 1982. This review has recently been updated and lead author, Fiona Stewart, tells us how the logo might look now, base on the current data.What does this update tell us?  Our overall findings can be summed up like this: antenatal steroids given to women at risk of preterm birth reduce the risk of infant mortality and morbidity. In other words, babies are more likely to survive and less likely to ha...
Source: Cochrane News and Events - December 10, 2020 Category: Information Technology Authors: Katie Abbotts Source Type: news